Table 1 Baseline characteristics of patients
Characteristic | SJOV (n = 36) | Nasal cannula (n = 36) |
|---|---|---|
Age (year) | 48.5 (42.0–57.0) | 50.0 (44.8–55.8) |
BMI (kg/m2) | 23.7 ± 2.6 | 22.8 ± 2.8 |
Male [n (%)] | 18 (50.0) | 19 (52.8) |
Tibetan [n (%)] | 24 (66.7) | 21 (58.3) |
ASA grade of III or severer [n (%)] | 3 (8.3) | 4 (11.1) |
Comorbidity [n (%)] | ||
Hypertension | 6 (16.7) | 12 (33.3) |
Coronary artery disease | 4 (11.4) | 1 (2.8) |
Diabetes | 0 (0.0) | 1 (2.8) |
COPD | 2 (5.6) | 0 (0.0) |
Asthma | 2 (5.6) | 2 (5.6) |
OSAHS | 6 (16.7) | 6 (16.7) |
Total | 14 (38.9) | 17 (47.2) |
Hemoglobin concentration (g/L) | 161.5 ± 22.5 | 157.8 ± 29.0 |
Erythrocytosis [n (%)] a | 15 (41.7) | 17 (47.2) |
Baseline vital signs | ||
Peripheral oxygen saturation (%) | 90.3 (2.2) | 90.3 (2.8) |
Original hypoxia [n (%)] b | 12 (33.3) | 13 (36.1) |
Mean blood pressure (mmHg) | 88.7 ± 18.0 | 96.1 ± 19.2 |
Heart rate (beat/mi) | 71.3 ± 13.2 | 73.0 ± 13.0 |
Procedural characteristics | ||
Procedure time (min) | 11.0 (8.5–14.8) | 10.5 (8.0–15.0) |
Total propofol dose (mg) | 120 (70–150) | 115 (85–150) |
Total alfentanil dose (ug) | 500 (0–1000) | 500 (0–725) |